Analysis of survival after radical surgery for stomach cancer in odessa regional cancer center

The survival of patients with the locally advanced stage of stomach cancer (SC), who underwent various variants of preventive lymphatic nodes dissection, was considered. The survival of patients was compared with the stage and T, N indexes. Lymphadenectomy D2 were effective and increased cumulative survival in patient`s group T4aNoMo, stage IIB and T4aN1Mo, stage III A, and in groups of patients where D2 lymphadenectomy were ineffective - T4bNoMo, stage ІІІB, T4bN1Мo, stage ІІІB and T4aN2Мo, stage IIIB. D2 were more efficient operation in the case of tumor serosa invasion and invasion to the peritoneal cavity (SE) in the absence of multiple metastases to the regional lymph nodes (N1 according to the 7th revision of the classification - 1-2 metastatic lymph nodes), and when the tumor infiltrated the surrounding organs (SI) and the presence of multiple regional metastases, D2 lymphodissection did not gave positive results, comparising with D1

Lymph node dissection impact on long-term survival rate of gastric cancer patients in Ukraine

Over a period of 2007-2011 188 stomach cancer (SC) patients have been included in the research in abdominal oncosurgical department of Odessa oncological center. Volume of lymph node dissections differed by quantity of lymph nodes to be removed. All patients were divided into three groups. Patients with D1 or D1+ lymph node dissections have been performed, totally 90 patients are included in group of historical control. In all cases so-called lymph node dissections for principal reasons have been executed. The multifactorial analysis of patients survival is implemented depending on a type of a lymph node dissections, a stage of the cancer, number of involved lymph nodes, involvement of the tumoral microcirculatory net (ly is carried out, v) signs of a perinevral invasion (Nev), availability of residual tumoral tissue (R), degree of a differentiation (G). Regardless of a disease stage, SC at 60 % of patients, represented with initially hematologicaly disseminated disease. 40 % of SC`s had no signs of intratumoral microcirculatory net involvement even in case of more than 15 regional lymph nodes are involved

The original formula for predicting the survival of gastric cancer patients undergoing surgical treatment

The purpose of this work was to find ways to predict the survival of gastric cancer patients. The study included 221 patients who were radically operated in the abdominal department of the Odessa Regional Oncology Center from 2007 to 2013. The life expectancy of this group of patients was measured in months. From the factors given in the article, only the age of the patient, the presence and invasion in neighboring organs and the number of organs resected during the operation were those factors that had a significant impact on the prognosis. A formula was obtained for the formal evaluation of the duration of patients. The results are preliminary. Conclusions. As a result of the regression analysis, a polynomial (formula) was obtained, which can be used to predict the survival of patients who underwent surgery for gastric cancer. There is a need to create clearer gradations of survival dependencies of cancer patients from different clinical and morphological situations. A mathematical apparatus with many variables can be used to create similar models for the analysis of survival in other types of pathology

ВИРУСНЫЙ ГЕПАТИТ А С РАЗВИТИЕМ АПЛАСТИЧЕСКОЙ АНЕМИИ У РЕБЕНКА 5 ЛЕТ (КЛИНИЧЕСКОЕ НАБЛЮДЕНИЕ)

.

Застосування сучасних методів діагностики у практиці оральної хірургії

У даному виданні висвітлені досягнення сучасної медицини, а саме методів діагостики захворювань щелепно-лицевої ділянки. У навчальному посібнику представлені такі методи діагностики, як цитологічне та гістологічне дослідження, рентгенологічне дослідження, комп’ютерна та магніто -резонансна томаграфія, артроскопия, ультразвукове дослідження та дерматоскопія. Навчальний посібник містить ілюстровані зображення наведених методів обстеження; В данном издании освещены достижения современной медицины, а именно методов диагостикы заболеваний челюстно-лицевой области. В учебном пособии представлены такие методы диагностики, как цитологическое и гистологическое исследования, рентгенологическое исследование, компьютерная и магнитно -резонансная томаграфия, артроскопия, ультразвуковое исследование и дерматоскопия. Учебное пособие содержит иллюстрированные изображения приведенных методов обследования; This publication highlights the achievements of modern medicine, namely, the methods of diagostic diseases of the maxillofacial area. The training manual presents such diagnostic methods as cytological and histological research, X-ray examination, computer and magnetoresonance tomography, arthroscopy, ultrasound and dermatoscopy. The tutorial contains illustrated images of the following survey methods

МУКОРМИКОЗ У ДЕТЕЙ С ГЕМАТОЛОГИЧЕСКИМИ И ОНКОЛОГИЧЕСКИМИ ЗАБОЛЕВАНИЯМИ В САНКТ-ПЕТЕРБУРГЕ

In prospective multicenter study were included 20 pediatriconcohematologic patients with mucormycosis. Age: 3 – 17 yy (median – 11), females – 60%. The diagnosiswas made according to EORTC/MSG 2008 criteria (post mortem – 25%). The main underlying disease was acutel eukemia (70%), risk factors – prolong severe neutropenia (median – 31 d) and lymphocytopenia (median – 33 d) after cytostatic chemotherapy or hematopoietic stem cells transplantation. Etiology agents were Lichtheimia corуmbifera, Rhizopus spp. and Rhizomucor spp. Main sites of infection were lungs (65%) and paranasal synuses (30%), dissemination – 45%. Antifungal therapy (amphotericin B lipid coplex, posaconazole, caspofungin, amphotericin B) was used in 75% patients, surgery – 30%. Overall mortality in 12 weeks was 70%.В проспективное многоцентровое исследование включили 20 детей с гематологическими и онкологическими заболеваниями, осложнившимися мукормикозом. Возраст – от 3 до 17 лет (медиана – 11 лет), девочки – 60%. Диагноз мукормикоза был установлен согласно критериям EORTC/MSG, 2008 (post mortem – 25%). Установлено, что мукормикоз развивается преимущественно у больных острым лейкозом (70%), на фоне длительного агранулоцитоза (медиана – 31 день) и лимфоцитопении (медиана – 33 дня) после интенсивной цитостатической и/или иммуносупрессивной терапии, а также трансплантации гемопоэтических стволовых клеток. Возбудители: Lichtheimia corуmbifera, Rhizopus spp. и Rhizomucor spp. Заболевание начинается с поражения легких (65%) и придаточных пазух носа (30%), диссеминацию выявили у 45% пациентов. Антимикотическую терапию (липидный комплекс амфотерицина В, позаконазол, каспофунгин, амфотерицин В) проводили 75% больных, хирургическое лечение – 30%. Общая летальность в течение 12 недель составила 70%

Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study

Background: Multisystem inflammatory syndrome in children (MIS-C), a hyperinflammatory condition associated with SARS-CoV-2 infection, has emerged as a serious illness in children worldwide. Immunoglobulin or glucocorticoids, or both, are currently recommended treatments. Methods: The Best Available Treatment Study evaluated immunomodulatory treatments for MIS-C in an international observational cohort. Analysis of the first 614 patients was previously reported. In this propensity-weighted cohort study, clinical and outcome data from children with suspected or proven MIS-C were collected onto a web-based Research Electronic Data Capture database. After excluding neonates and incomplete or duplicate records, inverse probability weighting was used to compare primary treatments with intravenous immunoglobulin, intravenous immunoglobulin plus glucocorticoids, or glucocorticoids alone, using intravenous immunoglobulin as the reference treatment. Primary outcomes were a composite of inotropic or ventilator support from the second day after treatment initiation, or death, and time to improvement on an ordinal clinical severity scale. Secondary outcomes included treatment escalation, clinical deterioration, fever, and coronary artery aneurysm occurrence and resolution. This study is registered with the ISRCTN registry, ISRCTN69546370. Findings: We enrolled 2101 children (aged 0 months to 19 years) with clinically diagnosed MIS-C from 39 countries between June 14, 2020, and April 25, 2022, and, following exclusions, 2009 patients were included for analysis (median age 8·0 years [IQR 4·2–11·4], 1191 [59·3%] male and 818 [40·7%] female, and 825 [41·1%] White). 680 (33·8%) patients received primary treatment with intravenous immunoglobulin, 698 (34·7%) with intravenous immunoglobulin plus glucocorticoids, 487 (24·2%) with glucocorticoids alone; 59 (2·9%) patients received other combinations, including biologicals, and 85 (4·2%) patients received no immunomodulators. There were no significant differences between treatments for primary outcomes for the 1586 patients with complete baseline and outcome data that were considered for primary analysis. Adjusted odds ratios for ventilation, inotropic support, or death were 1·09 (95% CI 0·75–1·58; corrected p value=1·00) for intravenous immunoglobulin plus glucocorticoids and 0·93 (0·58–1·47; corrected p value=1·00) for glucocorticoids alone, versus intravenous immunoglobulin alone. Adjusted average hazard ratios for time to improvement were 1·04 (95% CI 0·91–1·20; corrected p value=1·00) for intravenous immunoglobulin plus glucocorticoids, and 0·84 (0·70–1·00; corrected p value=0·22) for glucocorticoids alone, versus intravenous immunoglobulin alone. Treatment escalation was less frequent for intravenous immunoglobulin plus glucocorticoids (OR 0·15 [95% CI 0·11–0·20]; p<0·0001) and glucocorticoids alone (0·68 [0·50–0·93]; p=0·014) versus intravenous immunoglobulin alone. Persistent fever (from day 2 onward) was less common with intravenous immunoglobulin plus glucocorticoids compared with either intravenous immunoglobulin alone (OR 0·50 [95% CI 0·38–0·67]; p<0·0001) or glucocorticoids alone (0·63 [0·45–0·88]; p=0·0058). Coronary artery aneurysm occurrence and resolution did not differ significantly between treatment groups. Interpretation: Recovery rates, including occurrence and resolution of coronary artery aneurysms, were similar for primary treatment with intravenous immunoglobulin when compared to glucocorticoids or intravenous immunoglobulin plus glucocorticoids. Initial treatment with glucocorticoids appears to be a safe alternative to immunoglobulin or combined therapy, and might be advantageous in view of the cost and limited availability of intravenous immunoglobulin in many countries. Funding: Imperial College London, the European Union's Horizon 2020, Wellcome Trust, the Medical Research Foundation, UK National Institute for Health and Care Research, and National Institutes of Health

Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study

Background Multisystem inflammatory syndrome in children (MIS-C), a hyperinflammatory condition associated with SARS-CoV-2 infection, has emerged as a serious illness in children worldwide. Immunoglobulin or glucocorticoids, or both, are currently recommended treatments. Methods The Best Available Treatment Study evaluated immunomodulatory treatments for MIS-C in an international observational cohort. Analysis of the first 614 patients was previously reported. In this propensity-weighted cohort study, clinical and outcome data from children with suspected or proven MIS-C were collected onto a web-based Research Electronic Data Capture database. After excluding neonates and incomplete or duplicate records, inverse probability weighting was used to compare primary treatments with intravenous immunoglobulin, intravenous immunoglobulin plus glucocorticoids, or glucocorticoids alone, using intravenous immunoglobulin as the reference treatment. Primary outcomes were a composite of inotropic or ventilator support from the second day after treatment initiation, or death, and time to improvement on an ordinal clinical severity scale. Secondary outcomes included treatment escalation, clinical deterioration, fever, and coronary artery aneurysm occurrence and resolution. This study is registered with the ISRCTN registry, ISRCTN69546370. Findings We enrolled 2101 children (aged 0 months to 19 years) with clinically diagnosed MIS-C from 39 countries between June 14, 2020, and April 25, 2022, and, following exclusions, 2009 patients were included for analysis (median age 8·0 years [IQR 4·2–11·4], 1191 [59·3%] male and 818 [40·7%] female, and 825 [41·1%] White). 680 (33·8%) patients received primary treatment with intravenous immunoglobulin, 698 (34·7%) with intravenous immunoglobulin plus glucocorticoids, 487 (24·2%) with glucocorticoids alone; 59 (2·9%) patients received other combinations, including biologicals, and 85 (4·2%) patients received no immunomodulators. There were no significant differences between treatments for primary outcomes for the 1586 patients with complete baseline and outcome data that were considered for primary analysis. Adjusted odds ratios for ventilation, inotropic support, or death were 1·09 (95% CI 0·75–1·58; corrected p value=1·00) for intravenous immunoglobulin plus glucocorticoids and 0·93 (0·58–1·47; corrected p value=1·00) for glucocorticoids alone, versus intravenous immunoglobulin alone. Adjusted average hazard ratios for time to improvement were 1·04 (95% CI 0·91–1·20; corrected p value=1·00) for intravenous immunoglobulin plus glucocorticoids, and 0·84 (0·70–1·00; corrected p value=0·22) for glucocorticoids alone, versus intravenous immunoglobulin alone. Treatment escalation was less frequent for intravenous immunoglobulin plus glucocorticoids (OR 0·15 [95% CI 0·11–0·20]; p<0·0001) and glucocorticoids alone (0·68 [0·50–0·93]; p=0·014) versus intravenous immunoglobulin alone. Persistent fever (from day 2 onward) was less common with intravenous immunoglobulin plus glucocorticoids compared with either intravenous immunoglobulin alone (OR 0·50 [95% CI 0·38–0·67]; p<0·0001) or glucocorticoids alone (0·63 [0·45–0·88]; p=0·0058). Coronary artery aneurysm occurrence and resolution did not differ significantly between treatment groups. Interpretation Recovery rates, including occurrence and resolution of coronary artery aneurysms, were similar for primary treatment with intravenous immunoglobulin when compared to glucocorticoids or intravenous immunoglobulin plus glucocorticoids. Initial treatment with glucocorticoids appears to be a safe alternative to immunoglobulin or combined therapy, and might be advantageous in view of the cost and limited availability of intravenous immunoglobulin in many countries. Funding Imperial College London, the European Union's Horizon 2020, Wellcome Trust, the Medical Research Foundation, UK National Institute for Health and Care Research, and National Institutes of Health

A user's guide to the Encyclopedia of DNA elements (ENCODE)

The mission of the Encyclopedia of DNA Elements (ENCODE) Project is to enable the scientific and medical communities to interpret the human genome sequence and apply it to understand human biology and improve health. The ENCODE Consortium is integrating multiple technologies and approaches in a collective effort to discover and define the functional elements encoded in the human genome, including genes, transcripts, and transcriptional regulatory regions, together with their attendant chromatin states and DNA methylation patterns. In the process, standards to ensure high-quality data have been implemented, and novel algorithms have been developed to facilitate analysis. Data and derived results are made available through a freely accessible database. Here we provide an overview of the project and the resources it is generating and illustrate the application of ENCODE data to interpret the human genome